Case Reports

Gemicitabine-induced radiation recall phenomenon in 2 distinctive sites on the same patient


 

Radiation recall phenomenon is an acute inflammatory reaction that develops in previously irradiated areas after administration of inciting agents systemically. The most common agents are anticancer drugs.1 Gemcitabine, a fluorine-substituted deoxycytidine analog, is widely used as a chemotherapy medication. Its antitumor effect results from the blockade of DNA synthesis and DNA repair. It has been used in advanced pancreatic, non–small-cell lung, bladder, and ovarian cancers; soft-tissue sarcoma; and non-Hodgkin lymphoma.2 It has occasionally been reported to cause radiation recall phenomenon.3 The time between radiation and recall may range from weeks to almost a year.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Conventional chemo bests tyrosine kinase inhibitors in wild-type lung cancers
MDedge Hematology and Oncology
Cloud of questions hovers around electronic cigarettes
MDedge Hematology and Oncology
Phase III trial of PARP inhibitor for lung cancer launches
MDedge Hematology and Oncology
Case report: Choroidal metastases after targeted treatment with crizotinib
MDedge Hematology and Oncology
Medicare asks experts to weigh in on low-dose CT lung cancer screening
MDedge Hematology and Oncology
High tobacco use in subpopulations of Americans and rapid uptake in other countries are major concerns
MDedge Hematology and Oncology
Second ALK tyrosine kinase inhibitor approved for late-stage lung cancer
MDedge Hematology and Oncology
Panel recommends against low-dose CT for lung cancer in Medicare patients
MDedge Hematology and Oncology
Low-dose CT could up early lung cancer detection - at a price
MDedge Hematology and Oncology
Oncogenic drivers identified in 64% of lung adenocarcinomas
MDedge Hematology and Oncology